GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker4Good day, and thank you for standing by. Welcome to the GeneDx third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To start a question, please ...

GeneDx (Nasdaq: WGS) 3Q 2025 Earnings Presentation October 28, 2025 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expected full year 2025 reported revenue, growth in exome and genome revenue and volume, adjusted gross margin and a ...

BREAKING: Futures Mixed On Trump Comments; Fed, Huge Earnings Due Genetic testing leader GeneDx Holdings (WGS) is Monday's pick for IBD 50 Growth Stocks To Watch. The medical services stock is climbing in a seven-week-long consolidation pattern as the company's earnings report approaches. GeneDx turned profitable in 2024, and analysts expect meteoric earnings growth for its third quarter. The IBD 50 genetics testing stock was recently highlighted as an IBD Breakout… Take a Trial Today Get instant access to ...

目前，基因测序技术以前所未有的速度飞跃，催生了一个充满诱惑与争议的新领域：胚胎植入前多基因 风险检测（PGT-P）。它声称能够预测一个胚胎未来可能拥有的智力、外貌，甚至性格。这项技术不仅 正迅速商业化，更吸引了硅谷精英们的目光与投资——"定制婴儿"的想象，似乎正一步步照进现实。 然而，科学界正对这些预测的准确性提出质疑，伦理学家们也拉响了警报，称这种对非疾病性状的筛选 正在唤醒一个沉睡已久、令人不安的幽灵——"优生学"。当前，随着企业大胆推销"基因优化"方案，人 类社会被推到了一个十字路口：这究竟是进化史上的下一篇章，还是一个可能加剧不平等、扭曲我们对 人性的理解的陷阱？ 首先，让我们把视线聚焦到显微镜下。那里有一个半透明的斑点，它是一个人类囊胚。这个微小的生命 雏形，大约在精子和卵子结合后的第五天形成。这个细胞团细小如沙粒，却承载着未来一个独一无二的 个体的全部：它内含46条染色体、数千个基因，以及约60亿个DNA碱基对。这是构筑一个全新生命 的、最原始也是最详尽的"设计蓝图"。 如今，借助先进的基因测序技术，医生可以用激光在囊胚透明带上打开一个微小孔洞，用比发丝还细的 吸管取出几个细胞。就在这一刻，我们得 ...

Core Insights - Illumina's constellation mapped read technology is being piloted by GeneDx to enhance the identification of difficult-to-map genetic variants associated with rare diseases, outperforming traditional methods [1][3][5] Technology Performance - GeneDx utilized NovaSeq X Plus Systems with constellation kits to analyze 160 DNA samples from individuals with known genetic diseases, demonstrating the technology's ability to accurately identify complex structural variants and repeat expansions [3][6] - Constellation technology provides rapid insights into hard-to-diagnose conditions, showing flexibility across various sample types, including buccal, blood, and prenatal samples [4][5] Industry Impact - The technology is positioned to transform the understanding and treatment of rare diseases by combining speed, simplicity, and scientific rigor, which is essential for advancing precision medicine [5][6] - Illumina's constellation technology is set to be commercially available in the first half of 2026, indicating a significant advancement in genomic sequencing capabilities [8]

Core Insights - GeneDx is participating in the Sunshine Genetics Act, which aims to create the first state-backed genomic newborn screening program in the United States [1] Company Summary - GeneDx is involved in a pioneering initiative that focuses on genomic screening for newborns, indicating a significant advancement in genetic healthcare [1] Industry Summary - The establishment of a state-backed genomic newborn screening program represents a critical development in the healthcare industry, particularly in the field of genetics and early disease detection [1]

Core Insights - GeneDx announced pioneering scientific contributions to be presented at the American Society of Human Genetics (ASHG) Annual Meeting [1] Company Highlights - GeneDx is set to showcase its innovative research at a prominent genetics conference, indicating its active role in advancing genetic science [1]

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution. ...

Financial Data and Key Metrics Changes - The company has been focused on driving utilization, ensuring strong reimbursement coverage, and reducing turnaround times and costs to open up access [4] - The gross margin for chromosomal microarray tests has improved to 40% - 50% from a negative margin a few years ago [15] Business Line Data and Key Metrics Changes - The company has diagnosed more children with rare diseases than anyone else globally, with a data asset of over 3 million patients and more than 850,000 exomes and genomes [3][4] - The company is expanding its focus from expert geneticists to pediatric specialists, aiming to reduce the average age of diagnosis from five years to three years [12] Market Data and Key Metrics Changes - There are approximately 600,000 children diagnosed with developmental or intellectual delays, with 60,000 general pediatricians involved in diagnosing these conditions [13][14] - The company is targeting 12 Epic integrated systems by the end of the year, with a goal to connect to over 800 level three and four NICUs [22][25] Company Strategy and Development Direction - The company aims to become a household name in genetic testing, focusing on early diagnosis of rare diseases to alleviate the burden on families [2][17] - The acquisition of Fabric Genomics is intended to enhance the company's interpretation-as-a-service capabilities and expand into international markets without the need for extensive lab setups [36][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the new guidelines from the American Academy of Pediatrics, which could significantly shift the standard of care for children and increase testing utilization [12][17] - The company anticipates an 18 to 24-month timeline for significant changes in general pediatrician behavior regarding testing orders [19] Other Important Information - The company has made over 500 gene disease discoveries, contributing to a virtuous cycle of product improvement [9] - The company is focusing on expanding its biopharma business, which has shown potential for significant growth by matching patients to clinical trials [40][41] Q&A Session Summary Question: What is the anticipated mix between two-day and five-day tests? - The company charges more for ultra-rapid testing ($5,000 to $7,000) compared to the five-day turnaround tests, which are priced lower [29] Question: What is the size of the volume base that could be converted quickly? - The company is focusing on general pediatricians who are actively diagnosing children with developmental delays, aiming to convert existing orders through education and improved customer experience [13][15] Question: What does the Fabric Genomics acquisition add to the business? - The acquisition allows the company to leverage its data asset for interpretation-as-a-service globally, enhancing diagnostic accuracy and efficiency [36][38] Question: How is the company approaching the NICU opportunity? - The company is targeting NICUs to increase genetic testing utilization, with a current testing rate of less than 5% among NICU patients [24][25] Question: What are the company's expectations for the pediatric market? - The company expects early adopters among general pediatricians to begin ordering tests within the next 18 to 24 months, although significant impacts on revenue are not anticipated until later [21][19]